Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press Series of Journals Center for Evidence-Based and Translational Medicine of Wuhan University

The title
  • The title
  • The keywords
  • The author
Submit中文版

HomeArticlesVol 34,2024 No.12Detail

The analysis of disease burden of benign prostatic hyperplasia in China from 1990 to 2021

Published on Dec. 28, 2024Total Views: 907 timesTotal Downloads: 207 timesDownloadMobile

Author: HU Yan 1# WANG Xin 1# CHEN Xianyan 1 ZI Hao 2, 3 ZHU Cong 3, 4 FANG Cheng 3 ZHAO Yongwei 1, 4 ZENG Xiantao 3

Affiliation: 1. Department of Urology, Tai’an City Central Hospital, Tai'an 271099, Shandong Province, China 2. Evidence-Based Medicine Center, Xiangyang No. 1 People's Hospital Affiliated to Hubei University of Medicine, Xiangyang 441000, Hubei Province, China 3. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 4. Department of Urology, Tai’an City 88 Hospital, Tai'an 271001, Shandong Province, China

Keywords: Benign prostatic hyperplasia Disease burden Incidence Prevalence Disability-adjusted life years

DOI: 10.12173/j.issn.1004-5511.202410016

Reference: Hu Y, Wang X, Chen XY, Zi H, Zhu C, Fang C, Zhao YW, Zeng XT. The analysis of disease burden of benign prostatic hyperplasia in China from 1990 to 2021[J]. Yixue Xinzhi Zazhi, 2024, 34(12): 1329-1336. DOI: 10.12173/j.issn.1004-5511.202410016. [Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Objective  To analysis disease burden and its change trend of benign prostatic hyperplasia (BPH) in China from 1990 to 2021.

Methods  Data from the Global Burden of Disease Study 2021 (GBD 2021) database were obtained to analysis the incidence, prevalence, disability-adjusted life years (DALYs) of BPH in China from 1990 to 2021. Assessing temporal trends in the burden of disease by calculating estimated annual percentage changes (EAPC) in age standardised rates and comparative analysis of trends in the burden of BPH in China over time by social demographic index (SDI) were conducted.

Results In 2021, the incident cases of BPH in China were 3.244 million, with age-standardized incidence rate (ASIR) of 229.14 per 100,000. The prevalent cases were 2.311 million, with age-standardized prevalence rate (ASPR) of 2,315.23 per 100,000. The number of DALYs were 460,200 person year, with age-standardized DALYs rate (ASDR) of 45.84 per 100,000. The incidence, prevalence and DALYs rates of BPH in China in 2021 initially increased with age and then decreased, peaking in the 75-79 and 80-84 age groups, respectively. The ASIR [EAPC=-0.21, 95%CI(-0.36, -0.06)], ASPR [EAPC=-0.24, 95%CI(-0.41, -0.07)], and ASDR [EAPC=-0.25, 95%CI(-0.43, -0.09)] of BPH in China maintained a decreasing trend from 1990 to 2021, whereas the number of incident cases (122.16%), prevalent cases (132.50%), and DALYs (130.15%) showed an increasing trend. The ASIR, ASPR, and ASDR of BPH in China over the period 1990—2021 were much higher than those in high SDI countries.

Conclusion  The burden of BPH is high in China. Efforts should be made to enhance prostate health education for middle-aged and older men and to explore a BPH prevention and control system suitable for China's conditions. By promoting early detection and intervention, the progression of the disease can be delayed, reducing the overall disease burden.

Full-text
Please download the PDF version to read the full text: download
References

1. GBD 2019 Benign Prostatic Hyperplasia Collaborators. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Healthy Longev, 2022, 3(11): e754-e776. DOI: 10.1016/S2666-7568(22)00213-6.

2. Zhu C, Wang DQ, Zi H, et al. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019[J]. Mil Med Res, 2021, 8(1): 64. DOI: 10.1186/s40779-021-00359-8.

3. Chughtai B, Forde JC, Thomas DD, et al. Benign prostatic hyperplasia[J]. Nat Rev Dis Primers, 2016, 2: 16031. DOI: 10.1038/nrdp.2016.31.

4. Trueman P, Hood SC, Nayak US, et al. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK[J]. BJU Int, 1999, 83(4): 410-415. DOI: 10.1046/j.1464-410x. 1999.00966.x.

5. Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the health professionals follow-up study[J]. Urology, 2002, 59(2): 245-250. DOI: 10.1016/s0090-4295(01)01506-0.

6. Stroup SP, Palazzi-Churas K, Kopp RP, et al. Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008[J]. BJU Int, 2012, 109(1): 84-87. DOI: 10.1111/j.1464-410X.2011.10250.x.

7. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia[J]. J Urol, 2005, 173(4): 1256-1261. DOI: 10.1097/01.ju. 0000155709.37840.fe.

8. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440): 2133-2161. DOI: 10.1016/S0140-6736(24)00757-8.

9. GBD 2021 Demographics Collaborators. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440): 1989-2056. DOI: 10.1016/S0140-6736(24)00476-8.

10. GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440): 2100-2132. DOI: 10.1016/S0140-6736(24)00367-2.

11. Liu D, Li C, Li Y, et al. Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019[J]. World J Urol, 2023, 41(12): 3629-3634. DOI: 10.1007/s00345-023-04658-8.

12. Xu XF, Liu GX, Guo YS, et al. Global, regional, and national incidence and year lived with disability for benign prostatic hyperplasia from 1990 to 2019[J]. Am J Mens Health, 2021, 15(4): 15579883211036786. DOI: 10.1177/ 15579883211036786.

13. 陈慧瑛, 达骏, 姚海军, 等. 健康教育在良性前列腺增生症防治中的应用[J]. 中国全科医学, 2010, 13(17): 1843-1844. [Chen HY, Da J, Yao HJ, et al. Application of the health education in the diagnosis and treatment of benign prostatic hyperplasia[J]. Chinese General Practice, 2010, 13(17): 1843-1844.] DOI: 10.3969/j.issn.1007- 9572.2010.17.004.

14. 胡永涛, 邹志辉, 梁朝朝. 前列腺增生外科治疗新进展 [J]. 中华腔镜泌尿外科杂志(电子版), 2021, 15(1): 84-88. [Hu YT, Zou ZH, Liang CZ. New advances in surgical treatment of benign prostatic hyperplasia[J]. Chinese Journal of Endourology (Electronic Edition), 2021, 15(1): 84-88.] DOI: 10.3877/cma.j.issn.1674-3253. 2021.01.022.

15. 刘路, 程帆, 余伟民, 等. 良性前列腺增生症的微创治疗进展[J]. 武汉大学学报(医学版), 2022, 43(2): 332-337. [Liu L, Cheng F, Yu WM, et al. Progress in minimally invasive treatment of benign prostatic hyperplasia[J]. Medical Journal of Wuhan University, 2022, 43(2): 332-337.] DOI: 10.14188/j.1671-8852.2020.0810.

16. 廖海, 陈福兵, 杨勇, 等. Rezum水蒸气消融术治疗良性前列腺增生症的进展[J]. 微创泌尿外科杂志, 2023, 12(4): 283-286. [Liao H, Chen FB, Yang Y, et al. Progress of Rezum water vapour thermal therapy in the treatment of benign prostatic hyperplasia[J]. Journal of Minimally Invasive Urology, 2023, 12(4): 283-286.] DOI: 10.19558/j.cnki.10-1020/r.2023.04.014.

17. 屠凡倬, 陈宪艳, 曲亚萍, 等. 450 nm半导体蓝激光"打沟去垄法"治疗大体积良性前列腺增生的疗效观察[J]. 现代泌尿外科杂志, 2024, 29(5): 435-439. [Tu FZ, Chen XY, Qu YP, et al. Efficacy of "ditching and ridge removal" with 450 nm semiconductor blue laser in the treatment of large volume benign prostatic hyperplasia[J]. Journal of Modern Urology, 2024, 29(5): 435-439.] DOI: 10.3969/j.issn.1009-8291.2024.05.011.

18. Wang YB, Yang L, Deng YQ, et al. Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia: a univariable and multivariable Mendelian randomization study[J]. J Transl Med, 2022, 20(1): 495. DOI: 10.1186/s12967-022-03722-y.

19. Li BH, Deng T, Huang Q, et al. Body mass index and risk of prostate volume, international prostate symptom score, maximum urinary flow rate, and post-void residual in benign prostatic hyperplasia patients[J]. Am J Mens Health, 2019, 13(4): 1557988319870382. DOI: 10.1177/ 1557988319870382.

20. Kok ET, Schouten BW, Bohnen AM, et al. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study[J]. J Urol, 2009, 181(2): 710-716. DOI: 10.1016/j.juro.2008.10.025.

21. Wang SY, Cai Y, Hu X, et al. P. gingivalis in oral-prostate axis exacerbates benign prostatic hyperplasia via IL-6/IL-6R pathway[J]. Mil Med Res, 2024, 11(1): 30. DOI: 10.1186/s40779-024-00533-8.

22. 王聪聪, 张洁, 郭梦梦, 等. 肠道菌群与良性前列腺增生的关系和潜在机制[J]. 医学新知, 2024, 34(5): 582-592. [Wang CC, Zhang J, Guo MM, et al. Relationship and potential mechanisms between gut microbiota and benign prostatic hyperplasia[J]. Yixue Xinzhi Zazhi, 2024, 34(5): 582-592.] DOI: 10.12173/j.issn.1004-5511.202404010.

23. Huang Q, Li BH, Wang YB, et al. Clinical biomarker-based biological aging and risk of benign prostatic hyperplasia: a large prospective cohort study[J]. Aging Med (Milton), 2024, 7(3): 393-405. DOI: 10.1002/agm2.12331.

24. 钱信行, 顾佳敏, 陆沛文, 等. 良性前列腺增生多组学生物标志物的研究进展[J]. 医学新知, 2024, 34(2): 206-216. [Qian XH, Gu JM, Lu PW, et al. The research progress on multi-omics analysis biomarkers of benign prostatic hyperplasia[J]. Yixue Xinzhi Zazhi, 2024, 34(2): 206-216.] DOI: 10.12173/j.issn.1004-5511.202312069.

Popular Papers
© 2022 - 2025 Zhongnan Medical Journal Press of Zhongnan Hospital of Wuhan University|Support: Yufu Technology
About NM | Contact us